Icatibant Acetate News
Icatibant Acetate currently has 0 news articles, with 20 predicted indications.
This page combines the AI-predicted indications for Icatibant Acetate with the latest health news. Indications highlighted in orange have recent news coverage.
Drug Information
- Original indication: Icatibant Accord is indicated for symptomatic treatment of acute attacks of hereditary angioedema (HAE) in adults, adolescents and children aged 2 years and older, with C1 esterase inhibitor...
- Evidence level: L5
- Predicted indications (20):
- C1 inhibitor deficiency (100.0%)
- hereditary angioedema with C1Inh deficiency (100.0%)
- serpinopathy with toxic serpin polymerization (100.0%)
- hereditary angioedema (99.4%)
- pseudo-von Willebrand disease (99.2%)
- primary release disorder of platelets (99.1%)
- immune-mediated necrotizing myopathy (99.1%)
- antisynthetase syndrome (99.0%)
- Glanzmann thrombasthenia (99.0%)
- focal myositis (99.0%)
- Scott syndrome (98.8%)
- inflammatory myopathy with abundant macrophages (98.8%)
- idiopathic eosinophilic myositis (98.8%)
- Peyronie disease (98.6%)
- pancreatitis (98.0%)
- pernicious anemia (97.9%)
- thrombotic thrombocytopenic purpura (97.9%)
- inherited thrombophilia (97.4%)
- selective IgG immunodeficiency (97.3%)
- bleeding diathesis due to a collagen receptor defect (97.3%)
Related News (0)
No related news yet. When news mentions this drug, it will be collected and shown here automatically.
Disclaimer: The news on this page is collected automatically and is for research reference only; it does not constitute medical advice.